By Erica Teichert

Law360, New York (January 25, 2012, 7:59 PM ET) -- The U.S. Food and Drug Administration chastised Celgene Corp. and Novartis AG in letters released Wednesday for distributing potentially misleading claims in marketing materials that could affect doctors' decisions for prescribing the cancer therapies Abraxane and Gleevec.

One FDA letter focused on promotional materials for Novartis' Gleevec that the agency said overstated the effectiveness of the drug. The other note analyzed a white paper praising Celgene's Abraxane that the FDA said inflated Abraxane's efficacy and didn't mention potential risks and side effects that patients could suffer...